Table 4 Clinical characteristics by changes in serum copper concentration after zinc administration
decrease (n = 19) | Not decrease (n = 44) | ||||
|---|---|---|---|---|---|
Median | Range (Interquartile range) | Median | Range (Interquartile range) | p | |
GA (week) | 31.1 | 25.0–36.1 (29.5–33.0) | 32.2 | 26.4–36.1 (30.6–34.0) | 0.193 |
Birth weight (g) | 1264.0 | 624.0–2312.0 (1131.5–1802.0) | 1576.5 | 782.0–2550.0 (1282.5–1780.8) | 0.197 |
Dose (mg/kg/day) | 2.0 | 1.1–3.4 (1.5–2.5) | 2.1 | 1.0–3.8 (1.8–2.5) | 0.517 |
Administration period (day) | 13.0 | 4.0–14.0 (9.0–13.0) | 12.0 | 5.0–14.0 (10.0–13.0) | 0.724 |
At the start of administration | |||||
PNA (day) | 26.0 | 9.0–45.0 (16.5–29.0) | 25.5 | 12.0–72.0 (15.0–32.8) | 0.881 |
PMA (week) | 34.9 | 31.4–39.6 (33.6–35.9) | 36.0 | 32.9–39.3 (35.1–37.0) | 0.0235 |
Body weight (g) | 1740.0 | 866.0–2686.0 (1610.0–2052.5) | 1979.5 | 1382.0–2620.0 (1831.0–2257.3) | 0.0236 |
Serum zinc concentration (μg/dL) | 62.0 | 52.0–68.0 (57.5–66.0) | 57.0 | 40.0–69.0 (53.0–63.0) | 0.024 |
Serum copper concentration (μg/dL) | 42.0 | 26.0–86.0 (36.0–49.0) | 39.0 | 26.0–76.0 (31.5–46.3) | 0.222 |